HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Comparison of human immunodeficiency virus assays in window phase and elite controller samples: viral load distribution and implications for transmission risk.

AbstractBACKGROUND:
After 3 years of individual-donation nucleic acid test (ID-NAT) screening by the South African National Blood Service (SANBS), a repository of 73 human immunodeficiency virus antibody (anti-HIV)-negative window period (WP)-yield samples and 28 anti-HIV-positive, HIV-RNA-negative elite controllers (ECs) became available for comparison of a p24 antigen (p24 Ag) assay (Innogenetics), two viral load assays (Siemens branch DNA [bDNA] 3.0 and Abbott real-time polymerase chain reaction [RT-PCR]), and three triplex NAT assays (Novartis Diagnostics Ultrio and Ultrio-Plus and Roche TaqScreen) by replicate testing of dilutions.
STUDY DESIGN AND METHODS:
Viral loads were assessed by bDNA and RT-PCR assays and if below 100 copies (cps)/mL, by Ultrio limiting dilution probit analysis. The probability of virus transmission by WP and EC donations was estimated for different levels of the 50% minimum infectious dose (ID50 ) using Poisson distribution statistics.
RESULTS:
The equal distribution of WP donations plotted by log HIV-RNA levels indicated a random appearance of donors in the ramp-up phase. The HIV p24 Ag assay detected 45% of WP samples and the cutoff crossing point was estimated at 8140 (bDNA)/22,710 (RT-PCR) cps/mL. On replicate retesting of 40 HIV p24 Ag-negative ID-NAT WP-yield samples Ultrio minipool (MP)8, Ultrio-Plus MP8, and TaqScreen MP6 detected 79, 81, and 78%, respectively. Modeling with an estimated ID50 of 31.6 virions/RBC indicated that 15% of p24 Ag-negative ID-NAT WP-yield donations would have transmitted HIV if MP6-8 NAT had been used. Only 2% of RBC transfusions from ECs are estimated to be infectious with a worst-case ID50 estimate of 316 virions.
CONCLUSION:
Our analysis of viremia and infectivity of WP and EC donations enables comparison of the efficacy of NAT options in preventing HIV transmission risk.
AuthorsMarion Vermeulen, Charl Coleman, Josephine Mitchel, Ravi Reddy, Harry van Drimmelen, Tracy Fickett, Michael Busch, Nico Lelie
JournalTransfusion (Transfusion) Vol. 53 Issue 10 Pt 2 Pg. 2384-98 (Oct 2013) ISSN: 1537-2995 [Electronic] United States
PMID23445273 (Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
Copyright© 2013 American Association of Blood Banks.
Chemical References
  • HIV Core Protein p24
  • RNA, Viral
Topics
  • Algorithms
  • Asymptomatic Diseases
  • Blood Donors (statistics & numerical data)
  • Case-Control Studies
  • HIV Core Protein p24 (analysis, blood, immunology)
  • HIV Infections (blood, diagnosis, transmission)
  • HIV-1 (genetics, immunology, isolation & purification)
  • Humans
  • RNA, Viral (blood)
  • Real-Time Polymerase Chain Reaction (methods)
  • Risk Factors
  • Serologic Tests (methods)
  • South Africa
  • Viral Load (methods, physiology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: